|
|
||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
TRANSLATIONAL PHYSIOLOGY

1GI Cell Biology, Combined Program in Pediatric Gastroenterology and Nutrition, 2Division of Newborn Medicine, Children's Hospital, 3Molecular and Vascular Medicine and Renal Units and 4Division of Signal Transduction, Beth Israel Deaconess Medical Center, and Departments of 5Pediatrics and 6Medicine, Harvard Medical School, Boston, Massachusetts 02115; 7Division of Clinical Pharmacology, Johns Hopkins University, Baltimore, Maryland 21205; and 8Harvard Digestive Diseases Center, Boston, Massachusetts 02115
Submitted 22 August 2003 ; accepted in final form 24 December 2003
Aspartyl protease inhibitors (APIs) effectively extend the length and quality of life in human immunodeficiency virus (HIV)-infected patients, but dose-limiting side effects such as lipodystrophy, insulin resistance, and diarrhea have limited their clinical utility. Here, we show that the API nelfinavir induces a secretory form of diarrhea in HIV-infected patients. In vitro studies demonstrate that nelfinavir potentiates muscarinic stimulation of Cl- secretion by T84 human intestinal cell monolayers through amplification and prolongation of an apical membrane Ca2+-dependent Cl- conductance. This stimulated ion secretion is associated with increased magnitude and duration of muscarinically induced intracellular Ca2+ transients via activation of a long-lived, store-operated Ca2+ entry pathway. The enhanced intracellular Ca2+ signal is associated with uncoupling of the Cl- conductance from downregulatory intracellular mediators generated normally by muscarinic activation. These data show that APIs modulate Ca2+ signaling in secretory epithelial cells and identify a novel target for treatment of clinically important API side effects.
nelfinavir; clotrimazole; barium
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Visit Other APS Journals Online |